Success Metrics

Completion Rate
0%(0/1)
Active Trials
0(0%)
Terminated
1(50%)

Phase Distribution

Ph phase_1
1
50%
Ph phase_2
1
50%

Phase Distribution

1

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 1Safety & dosage
1(50.0%)
Phase 2Efficacy & side effects
1(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

2

all time

Status Distribution
Active(1)
Terminated(1)

Detailed Status

Not yet recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
0
Success Rate
0.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (50.0%)
Phase 21 (50.0%)

Trials by Status

not_yet_recruiting150%
terminated150%

Recent Activity

0 active trials
Showing 2 of 2
not_yet_recruitingphase_2

A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Patients With Advanced Non-Small Cell Lung Cancer

NCT07283198
terminatedphase_1

JSKN033 in Patients With Advanced or Metastatic Solid Malignant Tumors

NCT06226766

Clinical Trials (2)

Showing 2 of 2 trials
NCT07283198Phase 2

A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Patients With Advanced Non-Small Cell Lung Cancer

Not Yet Recruiting
NCT06226766Phase 1

JSKN033 in Patients With Advanced or Metastatic Solid Malignant Tumors

Terminated

All 2 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
2